Harbour gets Chinese rights to HanAll's biologics

Korean biotech HanAll Biopharma Co. Ltd. (KOSDAQ:009420) granted Harbour BioMed (Shanghai, China) rights to develop and commercialize HL161 and HL036 in China, including

Read the full 237 word article

How to gain access

Continue reading with a
two-week free trial.